Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03034694
Recruitment Status : Completed
First Posted : January 27, 2017
Last Update Posted : January 18, 2018
Sponsor:
Information provided by (Responsible Party):
Benjamin Kaffenberger, Ohio State University

Brief Summary:
The effect of teledermatology on length of hospital admission, length of stay, 30 day readmission rate, and antibiotic use in patients presenting with cellulitis vs pseudocellulitis in an academic emergency department setting.

Condition or disease Intervention/treatment Phase
Cellulitis Other: teledermatology consult Other: Routine Care Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Routine Care vs The use of teledermatology
Masking: Double (Participant, Investigator)
Primary Purpose: Diagnostic
Official Title: The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting
Study Start Date : January 2016
Actual Primary Completion Date : January 2018
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Routine Care
The first group will be randomized to routine care of receiving or not receiving a dermatology consult in the hospitalized setting based on the clinical decision of the hospitalist. The patients will see the research coordinator who will take images and for a teledermatology assessment, however, these assessments will not be placed in the chart and the treating hospitalist will not know.
Other: Routine Care
The patient will undergo imaging but this report will not be put into the chart.

Experimental: Teledermatology INtervention
The second arm will be patient randomized to teledermatology intervention. These patients will be imaged by the research coordinator, then the assessment will be placed in the chart for the hospitalist to see although final treatment decisions are still made by the hospitalist.
Other: teledermatology consult
teledermatology consult




Primary Outcome Measures :
  1. Length of Hospitalization [ Time Frame: 60 Days ]

Secondary Outcome Measures :
  1. Readmission rate [ Time Frame: 30 Days ]
  2. Frequency/Use of antibiotics [ Time Frame: 30 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Over 18
  • Admission for cellulitis-like symptoms, including but not limited to the following: tenderness, redness, swelling, expansive lesion

Exclusion Criteria:

  • pregnant
  • prisoner

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03034694


Locations
Layout table for location information
United States, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ohio State University
Investigators
Layout table for investigator information
Principal Investigator: Benjamin H Kaffenberger, MD OSU Dermatology

Layout table for additonal information
Responsible Party: Benjamin Kaffenberger, Assistant Professor, Ohio State University
ClinicalTrials.gov Identifier: NCT03034694     History of Changes
Other Study ID Numbers: 2015H0393
First Posted: January 27, 2017    Key Record Dates
Last Update Posted: January 18, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Additional relevant MeSH terms:
Layout table for MeSH terms
Cellulitis
Skin Diseases, Infectious
Infection
Suppuration
Connective Tissue Diseases
Inflammation
Pathologic Processes
Anti-Bacterial Agents
Anti-Infective Agents